Dyne Therapeutics (NASDAQ:DYN) Insider Douglas Kerr Sells 3,745 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Douglas Kerr sold 3,745 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $24.35, for a total value of $91,190.75. Following the sale, the insider directly owned 163,854 shares of the company’s stock, valued at $3,989,844.90. This trade represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Douglas Kerr also recently made the following trade(s):

• On Tuesday, September 8th, Douglas Kerr sold 1,290 shares of Dyne Therapeutics stock. The stock was sold at an average price of $18.88, for a total transaction of $24,355.20.

Dyne Therapeutics Stock Performance

Shares of DYN opened at $20.31 on Wednesday. The firm has a market cap of $3.79 billion, a price-to-earnings ratio of -6.10 and a beta of 1.08. The company’s fifty day moving average is $24.82 and its 200-day moving average is $20.49. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. Dyne Therapeutics, Inc. has a 12 month low of $11.92 and a 12 month high of $27.31.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). Equities analysts expect that Dyne Therapeutics, Inc. will post -3.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Hilton Head Capital Partners LLC bought a new stake in Dyne Therapeutics in the first quarter valued at about $26,000. Strs Ohio bought a new stake in shares of Dyne Therapeutics in the 4th quarter valued at approximately $51,000. Allworth Financial LP acquired a new position in Dyne Therapeutics during the second quarter worth $62,000. Aster Capital Management DIFC Ltd bought a new position in shares of Dyne Therapeutics in the fourth quarter valued at approximately $84,000. Finally, Steward Partners Investment Advisory LLC raised its holdings in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares during the last quarter. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics News Roundup

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Dyne announced that it will present additional six- and 12-month data from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) at the World Muscle Society and AANEM meetings beginning September 29-30. The data will include comparisons with a matched natural-history cohort and updated safety results. Dyne ACHIEVE trial data announcement
• Positive Sentiment: The ACHIEVE registrational expansion cohort is fully enrolled, and Dyne expects topline results in the first quarter of 2027. DYNE-101 also has FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, supporting the potential for an expedited development path. Quiver Quantitative ACHIEVE summary
• Neutral Sentiment: Call-option activity surged, with traders purchasing approximately 20,532 calls versus average daily volume of about 464. This may reflect speculative expectations for a rebound or upcoming data, but options activity does not confirm a fundamental improvement.
• Negative Sentiment: Reports said DYN fell heavily after a rival DM1 drug failed in Phase 3. Investors appear concerned that the setback could signal clinical or commercial risks for the DM1 field, even though Dyne’s own upcoming one-year data have not yet been released. RTT News report on rival DM1 failure
• Negative Sentiment: Several executives, including CEO John Cox, reported stock sales. The transactions were made to cover tax withholding on vested equity awards and were relatively small compared with their remaining holdings, limiting their direct significance, but the cluster of sales may add to cautious sentiment.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on DYN shares. Wall Street Zen cut Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Royal Bank Of Canada upped their price target on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday, July 30th. Sanford C. Bernstein lifted their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Cantor Fitzgerald assumed coverage on Dyne Therapeutics in a research report on Thursday, July 23rd. They issued an “overweight” rating on the stock. Finally, TD Cowen began coverage on shares of Dyne Therapeutics in a research note on Friday, June 26th. They issued a “buy” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $34.17.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.